Topic

Pennsylvania

A collection of 524 issues

How to Get Orladeyo (berotralstat) Covered by Aetna CVS Health in Pennsylvania: Forms, Appeals, and Alternative Strategies

Answer Box: Getting Orladeyo Covered by Aetna CVS Health in Pennsylvania Orladeyo (berotralstat) is excluded from most Aetna CVS Health formularies in 2024, requiring a formulary exception with documented failure of preferred alternatives like Takhzyro or Haegarda. Three-step process: 1) Submit prior authorization with HAE specialist documentation and C1-INH lab
6 min read

How to Get Elaprase (Idursulfase) Covered by Humana in Pennsylvania: Complete Appeals Guide with Forms and Timelines

Answer Box: Getting Elaprase (Idursulfase) Covered by Humana in Pennsylvania Elaprase (idursulfase) requires prior authorization from Humana for Hunter syndrome (MPS II) treatment. The fastest path to approval: (1) Submit PA request with enzymatic testing showing reduced iduronate-2-sulfatase activity and genetic confirmation of IDS gene mutation, (2) Include weight-based dosing
5 min read

How to Get Ibrance (palbociclib) Covered by Humana in Pennsylvania: Prior Authorization Guide and Appeals Process

Answer Box: Getting Ibrance (palbociclib) Covered by Humana in Pennsylvania You likely qualify if you have HR+/HER2- metastatic breast cancer confirmed by pathology. Humana requires prior authorization through their Clinical Pharmacy Review team or CoverMyMeds portal. First step today: Have your oncologist gather pathology reports, imaging showing metastatic disease,
5 min read

How to Get Amvuttra (Vutrisiran) Covered by Aetna CVS Health in Pennsylvania: Complete Guide to Prior Authorization and Appeals

Answer Box: Getting Amvuttra Covered by Aetna CVS Health in Pennsylvania Fastest path to approval: Submit prior authorization with genetic testing confirming TTR mutation, neuropathy documentation from a neurologist, and evidence of disease staging. Aetna typically places Amvuttra on Tier 4/5 with step therapy requirements. If denied, Pennsylvania'
7 min read

Work With Your Doctor to Get Alecensa (Alectinib) Approved by UnitedHealthcare in Pennsylvania: Forms, Appeals, and Success Strategies

Answer Box: Getting Alecensa Covered by UnitedHealthcare in Pennsylvania Getting Alecensa (alectinib) approved by UnitedHealthcare requires prior authorization with ALK-positive test results and clinical documentation. The fastest path: 1) Gather ALK fusion test results and treatment history, 2) Have your oncologist submit a medical necessity letter via UnitedHealthcare's
6 min read

Aetna (CVS Health) Coverage Criteria for Tagrisso (Osimertinib) in Pennsylvania: What Counts as "Medically Necessary"?

Answer Box: Getting Tagrisso (Osimertinib) Covered by Aetna (CVS Health) in Pennsylvania Aetna (CVS Health) requires prior authorization for Tagrisso with documented EGFR mutation testing (exon 19 deletion or L858R) and FDA-approved indication. Submit through CVS Caremark Specialty (1-866-814-5506) with complete clinical documentation. If denied, you have 180 days for
5 min read

How to Get Givlaari (givosiran) Covered by UnitedHealthcare in Pennsylvania: Complete Appeals Guide with Forms and Timelines

Answer Box: Getting Givlaari Covered by UnitedHealthcare in Pennsylvania Eligibility: UnitedHealthcare requires prior authorization for Givlaari (givosiran) with specific criteria: confirmed acute hepatic porphyria diagnosis, elevated ALA/PBG levels, at least 2 documented attacks in 6 months, and specialist involvement. Fastest Path: Have your hematologist, hepatologist, or gastroenterologist submit a
5 min read

Do You Qualify for Revlimid Coverage by UnitedHealthcare in Pennsylvania? Decision Tree & Next Steps

Answer Box: Getting Revlimid Covered by UnitedHealthcare in Pennsylvania You likely qualify for Revlimid (lenalidomide) coverage if you have multiple myeloma, MDS with 5q deletion, or an NCCN-supported indication. UnitedHealthcare requires prior authorization through OptumRx, REMS program enrollment, and comprehensive clinical documentation. First step today: Verify your diagnosis meets coverage
5 min read